BETHESDA, Md. — There is no statistical evidence that type 2 diabetes
negatively affects immune response to hepatitis B vaccine, according to
findings presented at the Annual Conference on Vaccine Research.
In 2011, the Advisory Committee on Immunization Practices recommended
that patients aged 19 to 59 years should be vaccinated against HBV as
soon as possible after a diagnosis of diabetes, and for those aged 60
years and older, the HBV vaccine
may be administered at the clinician’s discretion. These
recommendations were made primarily because patients with diabetes are
at an increased risk for HBV, Andrew Trofa, MD, of
GlaxoSmithKline Biologicals, said during his presentation. However,
there are limited data from prospective clinical trials of HBV
vaccination in people with diabetes, he said.
In a phase 4, open-label, international trial, Trofa and colleagues
assessed the seroprotection rate of the three-dose HBV vaccine series
in adult men and women with type 2 diabetes who had no history of HBV
infection or vaccination. The study included 512 participants with type 2 diabetes
and 256 controls without diabetes who were stratified into eight
subgroups by age (20-39 years, 40-49 years, 50-59 years, and 60 years
and older) and BMI (< 30 and ≥ 30). Seroprotection was defined as
antibodies to hepatitis B surface antigen (anti-HBs) of at least 10
mIU/mL.
Read more...Labels: diabetes, vaccine efficacy